CN Patent

CN117425659A — 哒嗪或被螺环胺取代的1,2,4-三嗪

Assigned to Janssen Pharmaceutica NV · Expires 2024-01-19 · 2y expired

What this patent protects

本发明涉及可用于哺乳动物的治疗和/或预防的药剂，包含此类化合物的药物组合物，以及它们作为可用于治疗疾病诸如癌症，包括但不限于白血病、骨髓增生异常综合征(MDS)和骨髓增生性肿瘤(MPN)；以及糖尿病的menin/MLL蛋白/蛋白相互作用抑制剂的用途。

USPTO Abstract

本发明涉及可用于哺乳动物的治疗和/或预防的药剂，包含此类化合物的药物组合物，以及它们作为可用于治疗疾病诸如癌症，包括但不限于白血病、骨髓增生异常综合征(MDS)和骨髓增生性肿瘤(MPN)；以及糖尿病的menin/MLL蛋白/蛋白相互作用抑制剂的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN117425659A
Jurisdiction
CN
Classification
—
Expires
2024-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.